JOHN McCAIN ARIZONA

CHAIRMAN
COMMITTEE ON COMMERCE,
SCIENCE, AND TRANSPORTATION
COMMITTEE ON ARMED SERVICES
COMMITTEE ON INDIAN AFFAIRS

United States Senate

June 16, 2004

241 RUSSELL SENATE OFFICE BUILDING WASHINGTON, DC 20510-0303 (202) 224-2235

> 4450 SOUTH RURAL ROAD SUITE B-130 TEMPE, AZ 85282 (480) 897-6289

2400 EAST ARIZONA BILTMORE CIRCLE SUITE 1150 PHOENIX, AZ 85016 (602) 952-2410

450 WEST PASEO REDONDO SUITE 200 TUCSON, AZ 85701 (520) 670-6334

TELEPHONE FOR HEARING IMPAIRED (202) 224-7132 (602) 952-0170

Mr. Paul Tubiana PO Box 21832 Lehigh Valley, PA 18002-1832

Dear Mr. Tubiana:

Thank you for contacting me concerning diabetes. I appreciate you taking the time to share your views with me on this important issue.

As you know, the incidence of diabetes is rising at an alarming rate and threatens to become a health care crisis. Diabetes is now afflicting 18.2 million Americans and this number could increase to between 45 and 50 million Americans by the year 2050 according to estimates by the Centers for Disease Control and Prevention (CDC). In Arizona, our large Native American and Hispanic populations are particularly at risk for developing this devastating disease.

Pancreatic islet cell transplantation has shown great promise as a potential diabetes treatment and cure. Last year, I cosponsored S. 518, the Pancreatic Islet Cell Transplantation Act of 2003. This bill would fund diabetes research, improve diabetes control and prevention strategies and technology, and work towards a cure. The Medicare Prescription Drug and Modernization Act of 2003, Public Law 108-173, included a provision of S. 518 to initiate a clinical investigation of pancreatic islet cell transplantation. This clinical investigation will be a major step toward improving the lives of diabetics throughout the country.

Recently, I cosponsored additional legislation expanding upon the goals of S. 518 to increase the supply of pancreatic islet cells for research and provide for better coordination of federal efforts on islet cell transplantation. Please be assured that I understand your concerns and will continue to work for those afflicted with diabetes.

Again, thank you for sharing your thoughts. Please feel free to contact me on this or any other matter of concern.

Sincerely,

John McCain United States Senator

JM/tm

08/17/2004

Paul Tubiana P.O. Box 21832 LeHigh Valley, PA 18002

Dear Mr. Tubiana,

Thank you for your interest in our Islet Cell Transplantation program. As you have learned through our recent telephone evaluation, the islet cell transplantation trials that are currently open can only be offered to patients with type I diabetes mellitus. Although you are not eligible for these trials today, I hope that with increasing knowledge concerning type II diabetes we will be able to offer patients like yourself new treatment options that will ease the burden of diabetes.

In the meantime, I have enclosed information about the Diabetes Research Institute and our current programs. Rest assured that we remain committed to our mission and will work to improve our treatment options for both type I and type II diabetes.

We thank you for your continued interest and support.

Sincerely,

Dr. Rodolfo Alejandro
Professor of Medicine
Co-Director, Cell Transplant Center
Director, Clinical Islet Transplantation



QUEST DIAGNOSTICS INCORPORATED

PATIENT INFORMATION TUBIANA, PAUL REPORT STATUS FINAL

ORDERING PHYSICIAN

GENDER: M FASTING: N

RECEIVED:

COLLECTED: 03/19/2003 03/20/2003 17:59 00:28

REPORTED:

03/21/2003

09:02

Test Name

In Range

Out of Range Reference Range

Lab

C-PEPTIDE

P 5000 6.2 H 0.6-3.2 ng/mL

TBR

NOTE: Factors such as obesity, high carbohydrate diet, and

inactivity tend to increase this value.

PERFORMING LABORATORY INFORMATION: